Tacrolimus-eluting nerve guidance conduit for enhanced regeneration in critical-sized peripheral nerve injuries

PROJECT SUMMARY/ABSTRACT This project aims to commercialize a state-of-the-art FK506-eluting, biodegradable nerve conduit designed to improve the treatment and outcomes of peripheral nerve injuries dramatically. Peripheral nerve injuries, which can result from a variety of causes, including accidents and surgical interventions, often lead to significant disabilities, chronic pain, and a reduction in quality of life for those affected. The limitations of current nerve repair techniques, such as autografts and synthetic conduits, highlight an urgent need for innovative solutions that can enhance nerve regeneration and functional recovery. Our proposal introduces a novel strategy that leverages the regenerative potential of FK506 (tacrolimus), an FDA- approved immunosuppressant known for its neuroprotective properties, incorporated into a biodegradable conduit. This conduit is engineered to deliver FK506 directly to the site of nerve injury in a controlled and sustained manner, optimizing the environment for nerve regeneration. In Phase II of our FK506-eluting nerve conduit project, we focus on three primary aims: 1) optimizing the manufacturing process for clinical-grade consistency, 2) validating the conduit’s efficacy in enhanced animal models to better mirror human nerve injury scenarios, and 3) conducting thorough biocompatibility and safety assessments to ensure no adverse effects. These steps are crucial for preparing the conduit for clinical trials, aiming to revolutionize peripheral nerve injury treatment by proving its superiority in promoting nerve regeneration and functional recovery. Successful completion will pave the way for regulatory submissions and set the stage for clinical applications, marking a significant leap toward improving patient outcomes in nerve repair. This project seeks to revolutionize peripheral nerve injury treatment, improving surgical outcomes and patient quality of life. It aligns with the National Institutes of Health (NIH) mission to advance biomedical research and public health by developing innovative solutions to reduce the burden of nerve injuries. The success of this project could significantly reduce healthcare costs by decreasing the need for repeated surgeries and long-term rehabilitation, addressing a critical gap in current treatment methodologies. The introduction of this FK506-eluting nerve conduit represents a significant advancement in regenerative medicine and nerve repair, potentially setting a new benchmark in therapeutic approaches for peripheral nerve injuries. Upon successful completion, this project will progress to Phase IIB, focused on scaling up production, extensive biocompatibility testing, and preparations for clinical trials, ultimately bringing this transformative technology to patients and clinicians.